Beam Therapeutics Inc.

BEAM Nasdaq SEC CIK 1745999
Follow Beam Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $307K −96.8% vs same quarter last year
Net income −$134.4M −19.4% vs same quarter last year
EPS, diluted −$1.28 −16.4% vs same quarter last year
Operating cash flow −$110.7M −35.9% vs same quarter last year
Revenue by quarter
$30.1M
$7.5M
$8.5M
$9.7M
$114.1M
$31.7M
$490K
$307K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200M$400MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$139.7M−$80M
FY24$63.5M−$376.7M
FY23$377.7M−$132.5M
FY22$60.9M−$289.1M
FY21$51.8M−$370.7M
FY20$24K−$194.6M
FY19$18K−$78.3M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1000000%−750000%−500000%−250000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−274.6%−57.2%
FY24−654.3%−593.1%
FY23−46.7%−35.1%
FY22−555.6%−474.5%
FY21−757%−715%
FY20−553166.7%−810800%
FY19−417522.2%−435144.4%
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$400M−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$360M
FY24−$356.2M
FY23−$182.9M
FY22−$26.4M
FY21−$113.1M
FY20−$112.1M
FY19−$84.5M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Beam Therapeutics
  • Healthcare median
−1000000%−750000%−500000%−250000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBeam TherapeuticsHealthcare median
FY25−57.2%−30.6%
FY24−593.1%−47%
FY23−35.1%−58%
FY22−474.5%−80.4%
FY21−715%−71.8%
FY20−810800%−62.2%
FY19−435144.4%−46.2%
FY18-−49.6%